The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists
Open accessAbstract
CC chemokine receptor 2 (CCR2) is one of 19 members of the chemokine receptor subfamily of human class A G-protein-coupled receptors. CCR2 is expressed on monocytes, immature dendritic cells, and T-cell subpopulations, and mediates their migration towards endogenous CC chemokine ligands such as CCL2 (ref. 1). CCR2 and its ligands are implicated in numerous inflammatory and neurodegenerative diseases including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, and diabetic nephropathy, as well as cancer. These disease associations have motivated numerous preclinical studies and clinical trials (see http://www.clinicaltrials.gov) in search of therapies that target the CCR2–chemokine axis. To aid drug discovery efforts, here we solve a structure of CCR2 in a ternary complex with an orthosteric (BMS-681 (ref. 6)) and allosteric (CCR2-RA-[R]) antagonist. BMS-681 inhibits chemokine binding by occupying the orthosteric pocket of the receptor in a previously unseen binding mode. CCR2-RA-[R] binds in a novel, highly druggable pocket that is the most intracellular allosteric site observed in class A G-protein-coupled receptors so far; this site spatially overlaps the G-protein-binding site in homologous receptors. CCR2-RA-[R] inhibits CCR2 non-competitively by blocking activation-associated conformational changes and formation of the G-protein-binding interface. The conformational signature of the conserved microswitch residues observed in double-antagonist-bound CCR2 resembles the most inactive G-protein-coupled receptor structures solved so far. Like other protein–protein interactions, receptor–chemokine complexes are considered challenging therapeutic targets for small molecules, and the present structure suggests diverse pocket epitopes that can be exploited to overcome obstacles in drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
Crystal structure of the human β2 adrenergic G-protein-coupled receptor
Rasmussen, S. G. F., Choi, H.-J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., Edwards, P. C., Burghammer, M., Ratnala, V. R. P., Sanishvili, R., Fischetti, R. F., et al. (2007) · Nature · doi:10.1038/nature06325 · Cited by 1,930
Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
Wu, B., Chien, E. Y. T., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., et al. (2010) · Science · doi:10.1126/science.1194396 · Cited by 1,782
Self-citationStructure-Function of the G Protein–Coupled Receptor Superfamily
Katritch, V., Cherezov, V., & Stevens, R. C. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032112-135923 · Cited by 1,054
Self-citationStructure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex
Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., et al. (2013) · Science · doi:10.1126/science.1241475 · Cited by 712
Self-citationCrystallizing membrane proteins using lipidic mesophases
Caffrey, M., & Cherezov, V. (2009) · Nature Protocols · doi:10.1038/nprot.2009.31 · Cited by 670
Self-citationStructural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling
Manglik, A., Kim, T. H., Masureel, M., Altenbach, C., Yang, Z., Hilger, D., Lerch, M. T., Kobilka, T. S., Thian, F. S., Hubbell, W. L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.043 · Cited by 665
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7376 · Cited by 501
Microscale Fluorescent Thermal Stability Assay for Membrane Proteins
Alexandrov, A. I., Mileni, M., Chien, E. Y. T., Hanson, M. A., & Stevens, R. C. (2008) · Structure · doi:10.1016/j.str.2008.02.004 · Cited by 449
Self-citationSpecific chemical and structural damage to proteins produced by synchrotron radiation
Weik, M., Ravelli, R. B. G., Kryger, G., McSweeney, S., Raves, M. L., Harel, M., Gros, P., Silman, I., Kroon, J., & Sussman, J. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.623 · Cited by 444
Structure of the human P2Y12 receptor in complex with an antithrombotic drug
Zhang, K., Zhang, J., Gao, Z.-G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., et al. (2014) · Nature · doi:10.1038/nature13083 · Cited by 397
Self-citationCrystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine
Qin, L., Kufareva, I., Holden, L. G., Wang, C., Zheng, Y., Zhao, C., Fenalti, G., Wu, H., Han, G. W., Cherezov, V., et al. (2015) · Science · doi:10.1126/science.1261064 · Cited by 381
Self-citationStaus, D. P., Strachan, R. T., Manglik, A., Pani, B., Kahsai, A. W., Kim, T. H., Wingler, L. M., Ahn, S., Chatterjee, A., Masoudi, A., et al. (2016) · Nature · doi:10.1038/nature18636 · Cited by 330
G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody
Hino, T., Arakawa, T., Iwanari, H., Yurugi-Kobayashi, T., Ikeda-Suno, C., Nakada-Nakura, Y., Kusano-Arai, O., Weyand, S., Shimamura, T., Nomura, N., et al. (2012) · Nature · doi:10.1038/nature10750 · Cited by 296
Structural basis for chemokine recognition and activation of a viral G protein–coupled receptor
Burg, J. S., Ingram, J. R., Venkatakrishnan, A. J., Jude, K. M., Dukkipati, A., Feinberg, E. N., Angelini, A., Waghray, D., Dror, R. O., Ploegh, H. L., et al. (2015) · Science · doi:10.1126/science.aaa5026 · Cited by 273
Pharmacological modulation of chemokine receptor function
Scholten, D., Canals, M., Maussang, D., Roumen, L., Smit, M., Wijtmans, M., de Graaf, C., Vischer, H., & Leurs, R. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01551.x · Cited by 248
Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344
Brodmerkel, C. M., Huber, R., Covington, M., Diamond, S., Hall, L., Collins, R., Leffet, L., Gallagher, K., Feldman, P., Collier, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5370 · Cited by 186
CCL2-CCR2 Signaling in Disease Pathogenesis
O’Connor, T., Borsig, L., & Heikenwalder, M. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316120920 · Cited by 160
Cherezov, V., Hanson, M. A., Griffith, M. T., Hilgart, M. C., Sanishvili, R., Venugopalan, N., Stepanov, S. A., Fischetti, R. F., Kühn, P., & Stevens, R. C. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2009.0142.focus · Cited by 156
Self-citationStructures of G protein-coupled receptors reveal new opportunities for drug discovery
Cooke, R. M., Brown, A., Marshall, F. H., & Mason, J. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.003 · Cited by 133
Chemokine Receptor Antagonists
Pease, J. E., & Horuk, R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300682j · Cited by 111
Berkhout, T. A., Blaney, F. E., Bridges, A. M., Cooper, D. G., Forbes, I. T., Gribble, A. D., Groot, P. H. E., Hardy, A., Ife, R. J., Kaur, R., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030862l · Cited by 91
“Chemokine receptors as therapeutic targets: Why aren’t there more drugs?”
Solari, R. C. E., Pease, J. E., & Begg, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.060 · Cited by 91
Andrews, G., Jones, C., & WREGGETT, K. A. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.039321 · Cited by 90
Nicholls, D., Tomkinson, N. P., Wiley, K. E., Brammall, A., Bowers, L., Grahames, C., Gaw, A. J., Meghani, P., Shelton, P. A., Wright, T. J., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044610 · Cited by 84
Multiple Binding Sites for Small-Molecule Antagonists at the CC Chemokine Receptor 2
Zweemer, A. J. M., Nederpelt, I., Vrieling, H., Hafith, S., Doornbos, M. L. J., de Vries, H., Abt, J. W., Gross, R. S., Stamos, D. P., Saunders, J., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.086850 · Cited by 63
Self-citationElucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5
Hall, S. E., Mao, A., Nicolaidou, V., Finelli, M. J., Wise, E. L., Nedjai, B., Kanjanapangka, J., Harirchian, P., Chen, D., Selchau, V., et al. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053470 · Cited by 55
Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2
Zweemer, A. J. M., Bunnik, J., Veenhuizen, M., Miraglia, F., Lenselink, E. B., Vilums, M., de Vries, H., Gibert, A., Thiele, S., ROSENKILDE, M. M., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093328 · Cited by 48
Self-citationDiscovery of Disubstituted Cyclohexanes as a New Class of CC Chemokine Receptor 2 Antagonists
Cherney, R. J., Mo, R., Meyer, D. T., Nelson, D. J., Lo, Y. C., Yang, G., Scherle, P., Mandlekar, S., Wasserman, Z. R., Jezak, H., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701488f · Cited by 46
Self-citationBlankenship, E., Vahedi‐Faridi, A., & Lodowski, D. T. (2015) · Structure · doi:10.1016/j.str.2015.09.015 · Cited by 43
Discovery of Potent, Orally Bioavailable Small‐Molecule Inhibitors of the Human CCR2 Receptor
Doyon, J., Coesemans, E., Boeckx, S., Buntinx, M., Hermans, B., Wauwe, J. P. V., Gilissen, R., Groot, A. H. J. D., Corens, D., & Lommen, G. V. (2008) · ChemMedChem · doi:10.1002/cmdc.200700276 · Cited by 17
Cited by
A guide to chemokines and their receptors
Hughes, C. E., & Nibbs, R. J. B. (2018) · The FEBS Journal · doi:10.1111/febs.14466 · Cited by 1,412
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Bajpai, G., Bredemeyer, A., Li, W., Zaitsev, K., Koenig, A. L., Lokshina, I., Mohan, J., Ivey, B., Hsiao, H.-M., Weinheimer, C., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314028 · Cited by 751
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
Common activation mechanism of class A GPCRs
Zhou, Q., Yang, D., Wu, M., Guo, Y., Guo, W., Zhong, L., Cai, X., Dai, A., Jang, W., Shakhnovich, E. I., et al. (2019) · eLife · doi:10.7554/elife.50279 · Cited by 632
Self-citation
Metadata
- Authors
- Zheng, Y., Qin, L., Zacarías, N. V. O., de Vries, H., Han, G. W., Gustavsson, M., Dabros, M., Zhao, C., Cherney, R. J., Carter, P., Stamos, D., Abagyan, R., Cherezov, V., Stevens, R. C., IJzerman, A. P., Heitman, L. H., Tebben, A., Kufareva, I., & Handel, T. M.
- Venue
- Nature
- Published
- 2016-12-07
- Volume
- 540
- Issue
- 7633
- Pages
- 458-461
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2560722699
- Cited by
- 284
- References
- 39
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.